Agents Used in Antiretroviral Therapy
Summary
- Rilpivirine is indicated in combination with other antiretroviral agents for treatment of HIV infection in treatment-naive adult patients with HIV-1 RNA ≤ 100,000 copies/mL in United States[FDA Rilpivirine]
- Also available as part of coformulations with emtricitabine/rilpivirine/tenofovir DF and emtricitabine/rilpivirine/tenofovir AF as 1-pill once-daily regimens and coformulated with dolutegravir as a switch regimen for patients virologically suppressed on a stable antiretroviral regimen for ≥ 6 months with no history of treatment failure and no known resistance to dolutegravir or rilpivirine[FDA DTG RPV]
- Rilpivirine is administered at a dose of 25 mg once daily with food
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content